Immune Checkpoint Inhibitors in Ovarian Cancer: Can We Bridge the Gap Between IMagynation and Reality?

Authors :: Konstantinopoulos PA
Cannistra SA
Source :: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2021 Jun 10; Vol. 39 (17), pp. 1833-1838. Date of Electronic Publication: 2021 Apr 23.
Publication Year :: 2021
Abstract: Competing Interests: Panagiotis A. KonstantinopoulosConsulting or Advisory Role: Merck, Vertex, AstraZeneca, Pfizer/EMD Serono, Tesaro, Bayer, Alkermes, Repare TherapeuticsResearch Funding: Pfizer, Lilly, Tesaro, Merck Serono, AstraZeneca, Merck, Bayer Stephen A. CannistraResearch Funding: Merck, Tesaro, AstraZeneca, Clovis Oncology, Bristol-Myers SquibbNo other potential conflicts of interest were reported.

Subjects :: Carcinoma, Ovarian Epithelial
Female
Humans
Immune Checkpoint Inhibitors
Ovarian Neoplasms drug therapy

Language :: English
ISSN :: 1527-7755
Volume :: 39
Issue :: 17
Database :: MEDLINE
Journal :: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Publication Type :: Editorial & Opinion
Accession number :: 33891471
Full Text :: https://doi.org/10.1200/JCO.21.00571

Full Text Access

Tools